An important topic of increasing attention discussed between CML patients and health professionals is the introduction of generics in CML treatment. Patients welcome that generics may improve patient access to more affordable therapies in many countries. However, patients also raise concerns about impact on their cancer when switched between different products for non-medical reasons, if their equivalence in terms of quality and efficacy is uncertain.
In May 2014, CML patient groups published a declaration calling governments, health authorities and healthcare professionals to minimize potential uncertainties and risks for patients with five measures. Thanks to our friends at Fundación Colombiana de Leucemia y Linfoma and the Max Foundation, a Spanish translation of the declaration is now available. See also our Generics knowledge base which is continuously updated.